OVERVIEW OF ACTIVITY

Optimal oncologic management of ovarian cancer begins with intensive surgical staging and cytoreduction, followed by primary chemotherapy and, for most patients, subsequent medical management when platinum-resistant relapsed disease prevails. Although many single-agent and combination cytotoxic recurrence regimens have been studied, only recently has the advent of antibody and small-molecule growth-inhibitory targeted agents been integrated into the ovarian cancer research milieu. It is hoped that the results from these trials will lead to the emergence of new therapeutic agents and changes or enhancements in the indications for existing treatment strategies, ultimately improving the duration and quality of life for patients with metastatic ovarian cancer. In order to offer optimal care to the ovarian cancer population — including the option of clinical trial participation — practicing oncologists must be well informed of these advances. By providing access to the latest research developments and expert perspectives through one-on-one discussion with leading investigators, Ovarian Cancer Update will assist medical and gynecologic oncologists with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Recognize the contributory roles of the specialized interdisciplinary team in achieving best-practice surgical and medical outcomes for patients with ovarian cancer.
• Compare and contrast the risks and benefits of intraperitoneal and intravenous chemotherapy regimens when devising management strategies for patients with optimally debulked Stage II and Stage III ovarian cancer.
• Develop an evidence-based algorithm for the systemic treatment of recurrent platinum-sensitive and platinum-resistant ovarian cancer that optimizes long-term patient outcome and quality of life.
• Summarize the existing data and ongoing clinical trials focused on angiogenesis inhibition of ovarian cancer, and identify patients who may benefit from this therapeutic approach.
• Consider the utility of evaluating CA125 serum levels and radiographic monitoring of patients with ovarian cancer that is in a state of remission.
• Understand the potential role of the risk-adapted use of maintenance systemic therapy for patients with ovarian cancer who have demonstrated an initial treatment response.
• Recall the scientific rationale for molecular-targeted agents under active investigation for the treatment of ovarian cancer.
• Counsel appropriately selected patients with ovarian cancer about the availability of and participation in ongoing clinical trials.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should review the CME information, listen to the CDs and complete the Post-test and Educational Assessment and Credit Form located on the our website at ResearchToPractice.com/OCU. ResearchToPractice.com/OCU includes an easy-to-use, interactive version of this monograph with links to relevant full-text articles, abstracts, trial information and other web resources indicated here in blue underlined text.

This program is supported by educational grants from Eli Lilly and Company, Genentech BioOncology and Ortho Biotech Products LP.

Home

EDITOR
Neil Love, MD

INTERVIEWS
Tate Thigpen, MD
- Select publications

Ursula A Matulonis, MD
- Select publications

Robert A Burger, MD
- Select publications

Bradley J Monk, MD
- Select publications

Ovarian Cancer Update:
A CME Audio Series and Activity

Faculty Disclosures

Editor's Office